MX9708989A - Terapia de celulas alogeneicas para el cancer despues del transplante de celulas madre alogeneicas. - Google Patents

Terapia de celulas alogeneicas para el cancer despues del transplante de celulas madre alogeneicas.

Info

Publication number
MX9708989A
MX9708989A MX9708989A MX9708989A MX9708989A MX 9708989 A MX9708989 A MX 9708989A MX 9708989 A MX9708989 A MX 9708989A MX 9708989 A MX9708989 A MX 9708989A MX 9708989 A MX9708989 A MX 9708989A
Authority
MX
Mexico
Prior art keywords
allogeneic
patients
cancer following
stem cell
cell therapy
Prior art date
Application number
MX9708989A
Other languages
English (en)
Other versions
MXPA97008989A (es
Inventor
Shimon Slavin
Original Assignee
Baxter Int
Hadasit Medical Res Services
And Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int, Hadasit Medical Res Services, And Dev Ltd filed Critical Baxter Int
Publication of MX9708989A publication Critical patent/MX9708989A/es
Publication of MXPA97008989A publication Critical patent/MXPA97008989A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/49—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46434—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen método y materiales para tratar pacientes con cáncer con tumores solidos que se han sometido a un régimen de terapia contra el cáncer que incluye el trasplante de médula osea alogeneica. Se administran linfocitos alogeneicos a estos pacientes. Los pacientes con tumores solidos y los pacientes hematopoyéticos también se tratan con linfocitos alogeneicos "pre-activados" por la exposicion in vitro a un activador de células T. El mismo activador o un activador de células T diferente se pueden administrar adicionalmente al paciente in vivo.
MXPA/A/1997/008989A 1995-05-25 1997-11-21 Terapia de celulas alogeneicas para el cancer despues del transplante de celulas madre alogeneicas MXPA97008989A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US449764 1982-12-14
US44976495A 1995-05-25 1995-05-25
PCT/US1996/007652 WO1996037208A1 (en) 1995-05-25 1996-05-24 Allogeneic cell therapy for cancer following allogeneic stem cell transplantation

Publications (2)

Publication Number Publication Date
MX9708989A true MX9708989A (es) 1998-03-31
MXPA97008989A MXPA97008989A (es) 1998-10-15

Family

ID=

Also Published As

Publication number Publication date
CA2220971A1 (en) 1996-11-28
EP0831860A1 (en) 1998-04-01
EP0831860B1 (en) 2004-10-20
AU5930396A (en) 1996-12-11
IL118418A (en) 2006-12-31
US6143292A (en) 2000-11-07
JPH11511746A (ja) 1999-10-12
IL118418A0 (en) 1996-09-12
DE69633668T2 (de) 2006-03-09
DE69633668D1 (de) 2004-11-25
WO1996037208A1 (en) 1996-11-28

Similar Documents

Publication Publication Date Title
CA2046916A1 (en) Methods and compositions for treatment of cancer using oligonucleotides
GR3034069T3 (en) Decontaminating blood components with 8-methoxypsoralen.
EP0637933A4 (en) METHOD AND DEVICE FOR IMAGING AND TREATING ORGANS AND TISSUES.
GEP20022648B (en) Method for Inducing T Cell Tolerance to a Tissue or Organ Graft
IL142728A0 (en) The use of dialkylfumarates for treating host-versus-graft reactions and auto-immune diseases
IL150258A0 (en) Cascade polymer complexes
SG1893G (en) Biologically active fragments of the human antihemophilic factor and method for their preparation and pharmaceutical preparations
IL197686A0 (en) Pharmaceutical compositions containing alpha-4 integrin antagonists and uses thereof in the treatment of multiple myeloma and diseases associated therewith
NZ281482A (en) The stimulation of erythropoiesis using thrombopoietin and erythropoietin
ATE300310T1 (de) Verfahren zur steigerung von hematopoietischen zellen
ATE236646T1 (de) Reaktive sauerstoffverbindungen enthaltende verbindungen zur induzierung von zelldifferentiation maligner zellen so wie leukämie
EP1135531A4 (en) METHODS OF INTRODUCING HETEROLOGOUS CELLS IN FISH
NZ319365A (en) Allogeneic mononuclear phagocytes introduced near injured site are used to promote axonal regeneration in the cns
MX9606559A (es) Terapia para el cancer usando linfotoxina.
AU533524B2 (en) 6-substituted-11-alkylene morphanthridines
MX9708989A (es) Terapia de celulas alogeneicas para el cancer despues del transplante de celulas madre alogeneicas.
CA2384418C (en) Use of cytokines, cells, and mitogens to inhibit graft versus host disease
Reece et al. Allogeneic bone marrow transplantation for Philadelphia-chromosome positive acute lymphoblastic leukemia
EP0280135A3 (en) Protein c-inhibitor (pci) as a pharmaceutical and diagnostic agent, process for the preparation of such a pharmaceutical or diagnostic agent and a composition containing pci
NZ501421A (en) Pharmaceutical composition containing cardenolides particularly uscharidin (uscharin) for treating excessive cell proliferation
CA2203528A1 (en) Methods and kits using macrophage stimulating protein
Rachamim et al. Potential role of CD34 stem cells in tolerance induction
IL97801A0 (en) Oligonucleotides,methods for in vitro tissue cell culture using the same and cosmetic compositions containing the same
EP1100515A4 (en) $ I (EX VIVO) TREATMENT OF ALLOGENIC AND XENOGENIC T CELLS USING gp39 ANTAGONISTS
AMAGASE et al. Response of A431 experimental human solid xenograft to mitomycin C in combination with human epidermal growth factor in mice